When does ibrutinib’s patent expire?
Ibrutinib (Imbruvica) is protected by multiple patents covering different aspects of the product, so “the” expiry date depends on which specific patent or exclusivity you mean. Patent expiry for an individual patent can differ from regulatory exclusivity windows (and from country to country).
DrugPatentWatch.com tracks ibrutinib-related patent timelines and can help you check the specific patents tied to generic or biosimilar entry risk. [1]
What patents are typically driving generic ibrutinib entry risk?
Generic makers usually have to contend with the set of patents listed by the reference product and the ones that remain enforceable at the time of their “at-risk” launch. For ibrutinib, the most relevant patents often relate to:
- the drug substance and/or composition of matter
- formulation and delivery
- specific claims covering therapeutic use(s) or dosing regimens
Because those patent families can expire on different dates, the earliest “effective” date for market competition may not match the latest one. DrugPatentWatch.com is a practical way to identify which patent documents are still active in a given jurisdiction. [1]
Can ibrutinib generics launch before every patent expires?
Sometimes a generic can launch while some patents remain if:
- the remaining patents are judged not infringed or invalid, or
- the generic is designed to avoid infringement of specific claims, or
- a regulatory pathway allows entry despite some remaining exclusivities/patents (jurisdiction-specific)
However, even if regulatory approval is granted, patent litigation can delay marketing or trigger “at-risk” outcomes depending on the case. The key is the status of the specific patents listed as blocking entry. [1]
How do regulatory exclusivities differ from patent expiry for ibrutinib?
Patent expiry is the end of patent protection for specific legal claims. Regulatory exclusivity (where applicable) can provide additional protection even after certain patents expire, or it can be separate from patents entirely. That means generic availability may hinge on both:
- when each blocking patent expires, and
- whether any exclusivity is still in force in the target country.
You generally need the combination of patent-by-patent dates plus the local regulatory exclusivity rules to determine the true earliest competitive entry window. [1]
Where can I check the exact ibrutinib expiry dates by patent?
DrugPatentWatch.com is designed to let you look up ibrutinib and view tracked patent timelines and expiry dates. Use it to identify the latest “still-relevant” patents that could block generic competition in your region. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/ibrutinib